Dr. Eads Discusses the Classification of Gastrointestinal NETs

Jennifer Eads, MD
Published: Friday, Jan 12, 2018



Jennifer Eads, MD, assistant professor, senior clinical instructor, department of medicine, University Hospitals Cleveland Medical Center, discusses the classification of gastrointestinal (GI) neuroendocrine tumors (NETs).

The current classification scheme for GI NETs involves using the tumor histology, the Ki-67, and the mitotic index, as parameters for placing a tumor and guiding treatment, says Eads.

Pathological and clinical studies have indicated that the most important determinate of aggressiveness is the tumor differentiation status, Eads explains. This will place the patient’s tumor in the less aggressive or more aggressive G3 category. Patients with poorly-differentiated and higher Ki-67 tumors are placed in the higher category and don’t do as well, with a poor median overall survival of under a year. As for the well-differentiated category, these patients usually have a higher median overall survival and response to therapy, says Eads.


Jennifer Eads, MD, assistant professor, senior clinical instructor, department of medicine, University Hospitals Cleveland Medical Center, discusses the classification of gastrointestinal (GI) neuroendocrine tumors (NETs).

The current classification scheme for GI NETs involves using the tumor histology, the Ki-67, and the mitotic index, as parameters for placing a tumor and guiding treatment, says Eads.

Pathological and clinical studies have indicated that the most important determinate of aggressiveness is the tumor differentiation status, Eads explains. This will place the patient’s tumor in the less aggressive or more aggressive G3 category. Patients with poorly-differentiated and higher Ki-67 tumors are placed in the higher category and don’t do as well, with a poor median overall survival of under a year. As for the well-differentiated category, these patients usually have a higher median overall survival and response to therapy, says Eads.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Medical Crossfire®: Bridging Emerging Data to Advance Treatment Planning for Hepatocellular Carcinoma: A Multidisciplinary Tumor BoardMar 31, 20182.0
Publication Bottom Border
Border Publication
x